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Background: Impella hemodynamic support has been shown to be cost-effective for patients receiving elective high-risk PCI, as illustrated in the 
PROTECT II Economic Study. It has also been included as a class 1 recommendation for cardiogenic shock.That study showed significant reductions 
in length-of-stay and readmissions for repeat revascularizations in the Impella arm compared to the IABP patients. This study assesses the cost 
savings of the Impella program at PinnacleHealth, focusing on patients receiving emergent hemodynamic support.
Methods: Patient financial and utilization data was extracted for patients experiencing an acute myocardial infarction (AMI), with PCI or CABG and 
no hemodynamic support, as well as for those patients with an AMI supported by IABP or Impella during 2009 and 2010. Cases were assigned to the 
appropriate category based upon diagnostic and procedural coding information. Data collected included both index stay as well as readmissions 
up to 90 days. Sample sizes were as follows: 2,262 AMI patients without support, 911 AMI patients with a CABG or PCI, 130 IABP-supported AMI 
patients, and 30 Impella-supported AMI patients.
Results: Preliminary results show that Impella-supported AMI patients experience 0.6 less days in the hospital than IABP-supported AMI patients 
or a 7% relative reduction. Equally important, Impella-supported AMI patients experience 41% fewer readmissions at 30 days compared to both 
the IABP-supported patients and to the patients receiving no hemodynamic support. This finding further strengthens the rationale to stabilize these 
patients with hemodynamic support.
Conclusions: For patients requiring emergent hemodynamic support, Impella support resulted in fewer hospital days and fewer hospital 
readmissions compared to patients receiving IABP support or no support. These economic measures have significant operational and health policy 
implications.
